Key Highlights

  • The FDA cleared Adicet Bio's Investigational New Drug (IND) application for ADI-212.
  • ADI-212 is being developed for metastatic castration-resistant prostate carcinoma (mCRPC).
  • Phase 1 enrollment is planned for the fourth quarter of 2026.
  • The clearance was announced August 27, 2026.

IND Clearance Opens the Door to Human Testing

Adicet Bio Inc. (NASDAQ:ACET) announced on August 27, 2026 that the FDA has cleared its Investigational New Drug (IND) application for ADI-212, a candidate being developed for metastatic castration-resistant prostate carcinoma (mCRPC) — a form of prostate cancer that has spread beyond the prostate and no longer responds to hormone-lowering therapy. IND clearance is the regulatory step that allows a company to begin dosing human patients in clinical trials, following FDA review of preclinical safety data and the proposed trial design.

What Comes Next

With the IND cleared, Adicet Bio (NASDAQ:ACET) has outlined plans to begin Phase 1 enrollment in the fourth quarter of 2026. As an early-stage, first-in-human study, the initial Phase 1 trial will primarily focus on establishing the safety profile and appropriate dosing of ADI-212, with efficacy signals typically emerging only as the study progresses and more patients are treated and followed.

mCRPC remains an area of significant unmet need, as treatment Options narrow considerably once the disease becomes resistant to standard hormone-based therapies, making new mechanisms of interest to both clinicians and developers in the space.

Market Reaction

Adicet Bio (NASDAQ:ACET) shares edged up 0.67% to $9.01, with the company's market Capitalization at approximately $84.35 million. The modest reaction is consistent with an early regulatory milestone that opens the door to clinical testing but does not yet provide any human efficacy or safety data.

What did the FDA clear for Adicet Bio?

The FDA cleared Adicet Bio's (NASDAQ:ACET) Investigational New Drug application for ADI-212, a candidate for metastatic castration-resistant prostate carcinoma.

When will Phase 1 enrollment begin?

Adicet Bio (NASDAQ:ACET) plans to begin Phase 1 enrollment in the fourth quarter of 2026.

What is mCRPC?

Metastatic castration-resistant prostate carcinoma (mCRPC) is a form of prostate cancer that has spread beyond the prostate and no longer responds to hormone-lowering treatment.